An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions
Solid Tumor
Interventions
DRUG

Senaparib capsules(20mg)

Single oral dose of Senaparib administered under fasting condition, 1\*20mg capsules in first intervention period and then 2\*10mg capsules in second intervention period (after washout period: at least 5 days)

DRUG

Senaparib capsules(10mg)

Single oral dose of Senaparib administered under fasting condition, 2\*10mg capsules in first intervention period and then 1\*20mg capsules in second intervention period (after washout period: at least 5 days)

Trial Locations (1)

Unknown

Wuhan Jinyintan Hospital (Wuhan Infectious Disease Hospital), Wuhan

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT07019194 - An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition | Biotech Hunter | Biotech Hunter